You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》康諾亞生物(02162.HK)公開超購近429倍及上限定價 一手中籤率僅6.5%
阿思達克 07-07 08:21
內地生物科技公司康諾亞生物-B(02162.HK)公布招股結果,計劃發售5,826.45萬股股份,當中約10%在港公開發售,公開發售錄超購428.97倍,經重新分配後,公開發售股數增至50%,國際發售項下初步提呈發售的發售股份已獲超購20.9倍。認購一手500股中籤率為6.5%,要認購3.5萬股(即70手)才穩獲一手。該股將於明日(7月8日)上市。摩根士丹利、中金及華泰國際為聯席保薦人。

每股發售價定於53.3元,為上限定價(每股招股價介乎50.5元至53.3元),

公司引入15名基石投資者,包括Invesco Ltd.、UBS Asset Management (Singapore)、Hillhouse Capital及Boyu Capital Opportunities Master Fund等,合共認購2,767.15萬股股份,佔緊隨全球發售完成後公司已發行股本約10.21%。

公司預計,集資所得款項淨額為29.42億元,約60%用於核心及主要產品的研發及商業化;約15%將用於公司其他在研產品的臨床前評估及臨床開發;約15%支付公司新生產及研發設施的租賃付款;約10%用於公司的一般企業及營運資金用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account